OakChart

NeuroSense Therapeutics Ltd

NRSNHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 3:59 PM ET

1.78-0.20 (-10.10%)
2026-11-12 01:08 CET
Market cap
3.76 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-11.13 USD m
Free cash flow, TTM
-7.68 USD m
EPS diluted, TTM
-8.73
P/E
-
Compare

Price

NRSN against its 20, 50 and 200-day averages
2050200earnings
0.005.0010.0015.0020.00204K407KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NRSNclose 1.7820-day 2.1450-day 4.39200-day 12.171.78

93.0% under the 52-week high of 25.40 on 19 Nov 2025. 52-week low 1.10 on 2 Nov 2026. Last 15 sessions, 150.0% high to low

Volume 1.67× normal · the line is the 50-bar volume average

Profile

NRSN
52-week range, 3% of the way up
1.1025.40

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Employees16
IPODec 09, 2021
Beta1.72
ATR, 14d0.45
Rel volume1.67
Short float2.09%
Insider own31.70%
Inst own0.95%

Snapshot

6 groups

Valuation

Index-
Market Cap3.38M
Enterprise Value-
Income-
Sales-
Book/sh-
Cash/sh-
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPODec 09, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C-
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio-
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-4.67
EPS next Q-
EPS this Y42.61%
EPS next Y7.43%
EPS next 5Y4.85%
EPS past 3/5Y25.89% 21.42%
Sales past 3/5Y- -
EPS Y/Y TTM31.09%
Sales Y/Y TTM-
EPS Q/Q59.58%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own31.70%
Insider Trans492.04%
Inst Own0.95%
Inst Trans-0.31%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-16.74%
SMA50-59.49%
SMA200-85.37%
Trades-

Technical

Shs Outstand1.90M
Shs Float1.30M
Short Float2.09%
Short Ratio0.87
Short Interest0.03M
52W High25.40 -92.99%
52W Low1.10 61.82%
Volatility20.73% 19.60%
ATR (14)0.45
RSI (14)32.54
Beta1.72
Rel Volume1.67
Avg Volume31.11K
Volume51,944

Performance

Perf Week25.35%
Perf Month-49.00%
Perf Quarter-79.91%
Perf Half Y-89.31%
Perf YTD-88.43%
Perf Year-90.76%
Perf 3Y-82.04%
Perf 5Y-
Perf 10Y-
Recom2.33
Target Price100.67
Prev Close1.98
Price1.78
Change %-10.10%

Peers

Mkt cap
TickerCompanyMkt cap
CLNNClene Inc60.40M
COYACoya Therapeutics Inc75.30M
MNOVMedicinova Inc69.40M
ALZNAlzamend Neuro Inc6.32M
ANVSAnnovis Bio Inc36.41M
PMNProMIS Neurosciences Inc33.72M
CRVOCervoMed Inc26.78M
INMBINmune Bio Inc34.05M
AMLXAmylyx Pharmaceuticals Inc4.09B
CGTXCognition Therapeutics Inc64.42M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Eisenberg OrChief Financial OfficerJun 16 '26Buy0.80250,000200,0001,504,050Jun 17 04:30 PM
Ben-Noon AlonChief Executive OfficerJun 16 '26Buy0.80250,000200,0004,534,233Jun 17 04:30 PM

News

latest 14 of 200
  • NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data (PR Newswire) -28.14%
  • NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 (PR Newswire) -9.75%
  • NeuroSense Files U.S. Patent Application for Traumatic Brain Injury (PR Newswire) -13.19%
  • NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones (PR Newswire)
  • NeuroSense Provides Update on Nasdaq Listing Compliance (PR Newswire)
  • NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference (PR Newswire) -26.62%
  • NeuroSense Provides Business Update and Progress for the First Half of 2026 (PR Newswire) -6.08%
  • NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire) -17.21%
  • NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval (FinanceWire)
  • NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS (PR Newswire)
  • NeuroSense Issues CEO Letter to Shareholders (PR Newswire) -5.46%
  • NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada (PR Newswire) -7.16%
  • NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS (PR Newswire) -7.14%
  • NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-3.900-3.900-0.8000.000.002
2025Q42026-03-31-4.700-1.416-0.8000.000.002
2025Q32025-11-26-0.800-0.874-0.8000.000.001
2025Q22025-08-01-2.754-4.452-2.8000.000.002
2025Q12025-05-28-2.086-2.086-2.1000.000.002
2024Q42025-04-07-0.800-3.000-1.5600.00-1
2024Q32024-12-18-2.400-2.200-2.169--1
2024Q22024-08-28-1.000-3.700-0.949--2
2024Q12024-06-24-7.000-4.100-7.016--2
2023Q42024-04-05-3.700-4.000-3.836--2
2023Q32023-11-280.900-5.2001.151--1
2023Q22023-08-16-6.200-5.900-7.671--2
2023Q12023-06-01-6.600-5.800-6.600--1
2022Q42023-03-22-5.400-5.600-5.347--1
2022Q32022-12-01-5.200--5.129--1
2022Q22022-08-31-6.000--6.033--1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-11.600-16.800-41.639--
2022FY-21.400-22.000-21.452--
2023FY-16.600-16.400-14.819--
2024FY-10.900-13.000-10.9770.00-
2025FY-8.800-6.995-8.8000.000.00
2026FY--5.050--0.00
2027FY--4.675--0.00
2028FY--7.580--10.00
2029FY-13.185--21.40
2030FY-7.490--162.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-05-201000.540.540.54
2026Q3S2026-04-071000.540.540.54
2026Q3S2026-03-311000.540.540.54
2026Q3S2025-11-261000.540.540.54
2026Q3S2025-11-111000.540.540.54
2026Q3S2025-11-101000.540.540.54
2026Q3S2025-11-091000.540.540.54
2026Q3S2025-11-081000.540.540.54
2026Q3S2025-11-071000.540.540.54
2026Q3S2025-11-061000.540.540.54
2026Q3S2025-11-051000.540.540.54
2026Q3S2025-11-041000.540.540.54
2026Q3S2025-11-031000.540.540.54
2026Q3S2025-11-021000.540.540.54

Estimate history

EPS, annual-12.592-29.14-41.639-21.452-14.819-10.977-8.732
Period2019202020212022202320242025
EPS, quarterly-5.347-6.6-7.6711.151-3.836-7.016-0.949-2.169-0.078
PeriodQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24
Sales, annual0000000
Period2019202020212022202320242025
Sales, quarterly000000000
PeriodQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24
Shares, annual0.0970.0970.5470.5890.7691.1611.628
Period2019202020212022202320242025
Shares, quarterly0.5890.590.6810.6810.7690.7790.9030.9923.229
PeriodQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.020.020.090.000.000.00
Gross Profit-0.02-0.02-0.02-0.02-0.09-0.00-0.000.00
Selling, General and Administrative Excl. Other11.0711.079.8812.0313.465.582.891.24
Research and Development6.236.235.707.276.423.082.500.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.09-11.09-9.90-12.05-13.55-5.59-2.89-1.24
Non-Operating Income (Expense)-0.03-0.03-0.040.200.07-0.030.060.01
Interest Expense0.010.010.310.450.021.150.000.00
Unusual Expense0.000.00-0.05-2.19-1.17-2.730.000.00
Net Income Before Taxes-11.13-11.13-10.21-10.11-12.34-4.04-2.83-1.22
Income Taxes0.000.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Consolidated Net Income-11.13-11.13-10.21-10.11-12.34-4.04-2.83-1.22
Net Income From Continuing Operations-11.13-11.13-10.21-10.11-12.34-4.04-2.83-1.22
Net Income-11.13-11.13-10.21-10.11-12.34-4.04-2.83-1.22
EPS (Recurring)-8.73-8.73-11.01-17.07-22.87-61.34-29.14-12.59
EPS (Basic, Before Extraordinaries)-8.73-8.73-10.98-14.82-21.45-41.64-29.14-12.59
EPS (Diluted)-8.73-8.73-10.98-14.82-21.45-41.64-29.14-12.59
EBITDA-11.07-11.07-9.88-12.03-13.46-5.58-2.88-
Stock Option Compensation Expense2.142.140.561.545.113.822.060.61
Shares Outstanding-1.631.160.770.590.550.100.10
Market Capitalization3.763.76------

Income statement, quarterly

Currency USD, millions
Metric2024Q32024Q22024Q12023Q42023Q32023Q22023Q1
Total Revenue-0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A-0.000.000.000.000.000.000.00
Gross Profit-0.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other-2.113.032.993.292.903.483.64
Research and Development-1.161.571.881.961.631.912.10
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income--2.11-3.03-2.99-3.29-2.90-3.48-3.64
Interest Expense-0.04-2.410.000.011.890.31
Unusual Expense-0.000.000.000.000.000.000.00
Net Income Before Taxes--2.15-0.86-5.40-2.950.78-5.23-3.89
Income Taxes-0.000.000.000.000.000.000.00
Consolidated Net Income--2.15-0.86-5.40-2.950.78-5.23-3.89
Net Income From Continuing Operations--2.15-0.86-5.40-2.950.78-5.23-3.89
Net Income--2.15-0.86-5.40-2.950.78-5.23-3.89
EPS (Recurring)--2.17-0.95-7.02-3.841.15-7.67-6.60
EPS (Basic, Before Extraordinaries)--2.17-0.95-7.02-3.841.15-7.67-6.60
EPS (Diluted)--2.17-0.95-7.02-3.841.15-7.67-6.60
Non-Operating Income (Expense)-0.002.170.000.343.690.140.06
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.220.240.17----
Shares Outstanding-0.990.900.780.770.680.680.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments0.213.412.687.1311.100.700.90
Short Term Receivables0.030.160.170.130.180.030.02
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.530.820.070.120.130.000.00
Total Current Assets0.784.402.927.3811.410.730.91
Net Property, Plant & Equipment0.230.150.250.310.020.010.01
Total Investments and Advances0.020.020.020.020.000.040.04
Intangible Assets0.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.00
Total Assets1.034.583.197.7111.430.780.95
Short Term Debt Incl. Current Port. of LT Debt0.100.070.070.060.000.000.00
Accounts Payable0.801.161.460.500.040.060.02
Other Current Liabilities1.620.761.931.160.560.070.01
Total Current Liabilities2.521.993.461.730.600.120.04
Long Term Debt0.070.000.070.151.830.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.001.410.220.000.000.00
Total Liabilities2.591.994.942.092.420.120.04
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity-1.562.58-1.765.629.010.660.92
Total Shareholders Equity-1.562.58-1.765.629.010.660.92
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity-1.562.58-1.765.629.010.660.92
Total Liabilities & Stockholders Equity1.034.583.197.7111.430.780.95
Book Value Per Share-0.962.22-2.299.5416.466.799.46
Tangible Book Value Per Share-0.962.22-2.299.5416.466.799.46
Full-Time Employees16151814114-
Price to Book Ratio0.89------
Return on Assets-397.11-263.45-185.53-128.94-66.19-326.18-
Return on Equity-2,174.98-2,880.11-523.68-168.75-83.62-358.66-
Return on Invested Capital--395.28--214.01-37.30-429.14-133.12
Quick Ratio0.312.210.844.2819.126.0824.68
Current Ratio0.312.210.844.2819.126.0824.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-11.13-11.13-10.21-10.11-12.34-4.04-2.83-1.22
Depreciation0.020.020.020.020.090.000.00-
Deferred Taxes & Investment Tax Credit0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)2.092.090.83-0.183.962.232.060.61
Funds from Operations-9.02-9.02-9.35-10.27-8.29-1.81-0.76-0.61
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital1.341.34-0.781.910.750.270.070.03
Cash from Operating Activities-7.67-7.67-10.14-8.35-7.54-1.54-0.69-0.58
Capital Expenditures-0.01-0.01-0.00-0.03-0.07-0.02-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.003.50-3.520.000.00-0.02
Purchase of Investments0.000.000.00-0.00-3.520.000.00-0.02
Sale Or Maturity of Investments0.000.000.003.50-0.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.010.003.47-3.59-0.02-0.01-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock4.434.4310.913.983.8710.660.511.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.434.4310.913.983.8710.660.511.42
Proceedsfrom Stock Options4.414.4110.913.970.000.800.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.001.240.000.00
Change in Long Term Debt0.000.000.000.000.001.240.000.00
Issuance of Long Term Debt0.000.000.000.000.001.240.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.100.000.00-0.00
Other Financing Activities Uses0.000.000.000.00-0.100.000.00-0.00
Cash from Financing Activities4.434.4310.913.983.7011.900.511.42
Exchange Rate Effect0.040.04-0.040.01-0.090.02--
Net Change in Cash-3.21-3.210.74-0.90-7.5210.36-0.190.81
Free Cash Flow-7.68-7.68-10.14-8.38-7.61-1.56-0.70-0.59

Balance sheet, quarterly

Currency USD, millions
Metric2024Q32024Q22024Q12023Q42023Q3
Cash & Short Term Investments-0.381.240.772.684.80
Short Term Receivables-0.410.380.420.170.31
Inventories-0.000.000.000.000.00
Other Current Assets-0.000.000.000.070.00
Total Current Assets-0.791.621.192.925.11
Net Property, Plant & Equipment-0.180.200.230.240.26
Total Investments and Advances-0.020.020.020.020.02
Intangible Assets-0.000.000.000.000.00
Other Assets-0.000.000.000.000.00
Total Assets-0.981.841.453.185.39
Short Term Debt Incl. Current Port. of LT Debt-0.000.000.000.070.00
Accounts Payable-1.391.482.381.460.91
Other Current Liabilities-2.392.022.151.931.90
Total Current Liabilities-3.783.514.543.462.81
Long Term Debt-0.020.040.060.070.08
Provision for Risks Charges-0.000.000.000.000.00
Other Liabilities-0.000.003.851.522.69
Total Liabilities-3.803.548.445.055.58
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value-0.000.000.000.000.00
Common Equity--2.82-1.70-6.99-1.87-0.20
Total Shareholders Equity--2.82-1.70-6.99-1.87-0.20
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity--2.82-1.70-6.99-1.87-0.20
Total Liabilities & Stockholders Equity-0.981.841.453.185.39
Book Value Per Share--2.85-1.89-8.98-2.44-0.29
Tangible Book Value Per Share--2.85-1.89-8.98-2.44-0.29
Full-Time Employees----18-
Return on Assets--356.64-173.59-377.38-207.24-157.09
Return on Equity-----602.40-300.13
Quick Ratio-0.210.460.260.841.82
Current Ratio-0.210.460.260.841.82

Cash flow, quarterly

Currency USD, millions
Metric2024Q32024Q22024Q12023Q42023Q3

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.09%0.0M1.3M24.99K
2026-10-152.01%0.0M1.3M22.54K
2026-09-302.15%0.0M1.3M19.73K
2026-09-153.06%0.0M1.3M18.52K
2026-08-311.88%0.0M1.2M13.01K
2026-08-141.96%0.0M1.2M11.28K
2026-07-312.20%0.0M1.2M10.74K
2026-07-152.35%0.0M1.2M7.91K
2026-06-302.51%0.0M1.2M8.07K
2026-06-152.11%0.0M1.2M7.89K
2026-05-291.54%0.0M1.2M7.46K
2026-05-152.04%0.0M1.2M8.02K
2026-04-302.39%0.0M1.2M8.18K
2026-04-152.73%0.0M1.2M9.39K
2026-03-312.14%0.0M1.4M10.49K
2026-03-132.10%0.0M1.2M11.06K
2026-02-272.16%0.0M1.2M13.36K
2026-02-131.68%0.0M1.2M16.64K
2026-01-302.40%0.0M1.2M16.76K
2026-01-152.46%0.0M1.2M16.10K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-07-31EFFECTEffectiveness filing by commission orderSEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-30F-3/ASEC
2026-07-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-22SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-06-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-09SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-04-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-28SEC
2026-04-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-24SEC
2026-04-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-06SEC
2026-04-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-03SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-26SEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-313Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06400.00K200
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Independent Advisor Alliance0.28%
Yorkville Advisors Global, LP0.22%
COMMONWEALTH EQUITY SERVICES, LLC0.06%
PNC FINANCIAL SERVICES GROUP, INC.0.06%
UBS Group AG0.05%
Pathstone Holdings, LLC0.05%
GEODE CAPITAL MANAGEMENT, LLC0.04%
SBI Securities Co., Ltd.0.03%
XTX Topco Ltd0.03%
Creative Planning0.03%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND514.57%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND469.88%
State Street(R) SPDR(R) Bloomberg Emerging Markets Local Bond ETF90.24%
iShares International Treasury Bond ETF38.11%
iShares Core International Aggregate Bond ETF30.05%
State Street(R) SPDR(R) Bloomberg International Treasury Bond ETF11.10%
Goldman Sachs Global Core Fixed Income Fund7.07%
TCW Global Bond Fund0.40%
SA Wellington Strategic Multi-Asset Portfolio0.35%
iShares Global Government Bond USD Hedged Active ETF0.14%

OakChart. NRSN. Cached 15 minutes.

Some panels did not load: ratings.